

<b>Enclosure No:</b>	<b>9/AWMSG/1013</b>
<b>Agenda Item No:</b>	13 – Minutes of AWPAG meeting September 2013
<b>Author:</b>	All Wales Prescribing Advisory Group
<b>Contact:</b>	Tel: 029 20716900 E-Mail: <a href="mailto:awttc@wales.nhs.uk">awttc@wales.nhs.uk</a>

## **ALL WALES PRESCRIBING ADVISORY GROUP**

**Minutes of meeting held**  
**Thursday, 12<sup>th</sup> September 2013 commencing 9.30 am**  
**At the St Michael's Centre, 10a Pen Y Pound, Abergavenny, NP7 5UD**

### **Voting members**

Mrs Louise Howard-Baker (Chair)	Pharmacist, Betsi Cadwaladr
Mrs Jane Barnard	Lay member
Mr Alan Clatworthy	Pharmacist, Abertawe Bro Morgannwg
Mr Stefan Fec	Community Pharmacist
Miss Sophie Harding	Pharmacist, Velindre
Mrs Sarah Isaac	Pharmacist, Hywel Dda
Dr Susannah Jacks	GP, Aneurin Bevan
Dr Sue Jeffs (Vice Chair)	Consultant, Aneurin Bevan
Mrs Robyn Miles	Wales Industry Group
Ms Katie Morris	Pharmacist, Cardiff and Vale
Mrs Marnel Owen	Representing other professions eligible to prescribe
Dr Hamsaraj Shetty	Consultant, Cardiff and Vale
Dr Mark Walker	GP, Betsi Cadwaladr
Dr Sean Young	GP, Abertawe Bro Morgannwg
Mrs Bev Woods	Pharmacist, Cwm Taf

### **In attendance (non-voting)**

Mr Andrew Evans, Welsh Government  
Ms Kath Haines, AWTTTC  
Mr Jamie Hayes, AWTTTC  
Mrs Kate Jenkins, AWTTTC  
Miss Karen Jones, AWTTTC  
Miss Rosie Thompson, AWTTTC  
Mr Phil Groom, ABPI Cymru Wales

### **Key of abbreviations**

AWMSG	All Wales Medicines Strategy Group
AWMSGSC	All Wales Medicines Strategy Group Steering Committee
AWPAG	All Wales Prescribing Advisory Group
AWTTTC	All Wales Therapeutics and Toxicology Centre
CASPA	Comparative Analysis System for Prescribing Audit
CEPP	Clinical Effectiveness Prescribing Programme (Formerly called the Prescribing Incentive Scheme)
CPW	Community Pharmacy Wales
DH	Department of Health
GP	General Practitioner

MHRA	Medicines Health and Regulatory Authority
MMPB	Medicines Management Programme Board
NMG	New Medicines Group
NICE	National Institute for Health and Clinical Excellence
NSAIDs	Non steroidal anti inflammatory drugs
NWIS	NHS Wales Informatics Service
PSU	Prescribing Support Unit
SLA	Service Level Agreement
T&FG	Task and Finish Group
UHB	University Health Board
WAPSU	Welsh Analytical Prescribing Support Unit
WG	Welsh Government
WeMeReC	Welsh Medicines Resource Centre

## 1.0 Welcome & introduction

The Chair opened the meeting, invited members to introduce themselves and welcomed Ms Katie Morris, deputising for Mrs Fiona Walker, to her first meeting.

## 2.0 Apologies

Dr Tessa Lewis	GP, Aneurin Bevan
Dr Ashok Rayani	GPC Wales
Dr Richard Greville	Director ABPI
Mrs Fiona Walker	Pharmacist, Cardiff and Vale
Mr Paul Fleming	British Generics Manufacturers
Mr Jonathan Simms	Pharmacist, Aneurin Bevan
Mrs Sian Evans	Pharmaceutical Public Health Wales

## 3.0 Declaration of interest.

The chair asked all members to complete a declaration of interest for the year September 2013 to September 2014. Mrs Robyn Miles and Mr Phil Groom both declared interests pertinent to the meeting.

## 4.0 Chair's report

The Chairman announced that Dr Sue Jeffs had been appointed Deputy AWPAG Chairman by the AWMSG Steering Committee.

## 5.0 Minutes of Previous meeting

The minutes of the previous meeting were checked for accuracy. It was agreed that the minutes were an accurate reflection of the proceedings.

### 5.1 Matters arising:

**Medicines Reminder Chart NWIS Letter.** The Chairman informed the meeting that Dr Tessa Lewis had been in contact with NWIS and the Chief Information Officer has promised a response.

**Availability of Welsh Version of AWMSG Patient information leaflet: Medicines for mild to moderate pain relief.** The Chairman informed the group that this was now available on the AWMSG website.

**Wales Audit Office Review of Primary Care Prescribing report.** The Chairman informed the group that the All Wales draft document was still in preparation and would now be presented at AWPAG in December 2013.

**Prescribing Status of dronedarone and drugs used for arrhythmia.** The Chairman informed the group that consultation responses had now been received.

## **6.0 Papers endorsed by AWMSG**

The chairman gave brief feedback on the following papers endorsed by AWMSG meetings held 12<sup>th</sup> June and 17<sup>th</sup> July 2013:

### All Wales Common Ailments Service Formulary

Further to AWMSG approval, it was agreed by AWPAG that the Formulary should be made more widely available to all prescribers as a good practice document. It was noted that some amendments are required to ensure a second choice medicine is available in circumstances where the first choice medicine is not available.

#### **ACTION**

**Formulary to be updated and process for future amendments clarified**

### National Prescribing Indicators 2012–2013: Analysis of Antidepressant and Dosulepin Prescribing

### National Prescribing Indicators 2012–2013: Analysis of Prescribing Data to March 2013

Ms Kath Haines informed the group that the analysis to June 2013 would soon be available.

### Opioids in Palliative Care – A Patient Information Manual.

This was well received by AWMSG.

## **7.0 Prescribing of denosumab (Prolia®) in Wales (Review)**

The Chairman presented the paper and invited comment from the group. Dr Sean Young expressed concern surrounding the availability of Vitamin D testing in primary care. The Chair clarified the purpose of the document is to provide a template for local adaptation.

#### **ACTION**

**Chairman to seek clarification from Health Boards regarding the availability of Vitamin D testing before the paper is presented to AWMSG**

## **8.0 All Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation**

The Chairman presented the paper and invited comment from the group. Dr Hamsaraj Shetty raised the issue of renal failure and after a brief discussion it was agreed a statement referring to the annual review of patients on oral anticoagulants should be included.

#### **ACTION**

**Paper to be amended before being presented to AWMSG**

## **9.0 Tramadol Prescribing – Educational Resource Materials**

The Chairman invited Ms Kath Haines to provide the background. Ms Kath Haines informed members that the work had been overseen by Ms Karen Jones and, in turn, asked her to provide an explanation of the resource materials. It was agreed that a pilot of the audit would be undertaken in primary and secondary care. The group agreed that Tramadol should be part of a wider pain management resource pack; however, in light of Welsh Government's priority, the Tramadol audit should be disseminated in the first instance. It was suggested that a wider pain audit for 2014-2015 required further discussion. There was concern in relation to the patient information leaflet. Members suggested refinements to the maps within the draft WeMeReC bulletin. The draft audit for emergency departments currently in development was discussed. It was suggested that clinical directors of emergency departments should be approached as part of the consultation process.

#### **ACTION**

**Pilot to be undertaken in primary and secondary care**

**AWTTC to clarify legal aspects of the patient information leaflet**

**AWTTC to refine the maps within the WeMeReC bulletin**

### **10.0 Proposed AWMSG National Prescribing Indicators 2014-15**

The Chairman opened the discussion and asked members to consider the recommendations. There were no comments from the group and the Chairman invited Mrs Kate Jenkins to present the paper in more detail and in addition the justification and rationale for the proposals.

Revisions to antidepressant drug basket and removal of the relevant target of the current National Prescribing Indicators. The suggested new National Prescribing Indicators were Tramadol prescribing and Yellow Card reporting and the current target for dosulepin National Prescribing Indicator is to be retained.

The Chairman welcomed Ms Emma Carey, Pharmacovigilance Pharmacist for Yellow Card Centre Wales, who informed the meeting of the reason for including Yellow Cards for adverse drug reactions as a National Prescribing Indicator. This was briefly discussed and it was agreed that the proposed measure for Yellow Card reporting should be changed to 1 Yellow Card per 2,000 patient population. AWPAG agreed the proposed AWMSG National Prescribing Indicators for 2014-2015.

#### **ACTION**

**WAPSU to update National Prescribing Indicator paper 2014-2015, for consultation during October 2013 and AWMSG Steering Committee on 17<sup>th</sup> December 2013**

### **11.0 Proposed AWMSG Local Comparators 2014-15**

Mrs Kate Jenkins presented a summary of the proposed local comparators for 2014-2015. The volume of local comparators was raised as a concern and subsequently discussed. It was agreed that primary care advice, via the Chief Pharmacists Committee, should be sought when making decisions on local comparators.

#### **ACTION**

**AWTTC to approach the Chair of the Chief Pharmacists primary care group  
Updated document to be brought back to AWPAG on 5<sup>th</sup> December 2013**

### **12.0 Primary Care Prescribing Analysis – Gluten Free**

Mrs Kate Jenkins informed the group that since the paper had been presented to AWMSG Steering Committee, AWTTC has received belated comments from Coeliac UK. Whilst the comments were relevant to the paper they did not constitute any major changes to the document. Some minor grammatical changes were suggested.

#### **ACTION**

**WAPSU to make minor changes before submission to AWMSG 16<sup>th</sup> October 2013**

### **13.0 BNF Chapter Analysis 2012-13**

Ms Kath Haines presented a paper which had been prepared following a request from the Chief Pharmaceutical Officer, Welsh Government. This was discussed at length, in particular the effect of 28 day prescribing, free prescriptions, deprivation and disease prevalence on the figures. It was agreed that the paper would be presented to AWMSG steering committee with a recommendation to concentrate on one BNF chapter.

#### **ACTION**

**AWTTC to take recommendation to AWMSG Steering Committee**

Dr Hamsaraj Shetty and Mr Alan Clatworthy left the meeting

### **14.0 Erectile Dysfunction – Department of Health proposal**

Mr Andrew Evans informed the group that DoH had written to Welsh Government with proposed changes to guidance in relation to the prescribing of tadalafil. Members were informed that WG had submitted a response to DoH. It was proposed that once the DoH legislative changes were available, AWPAG would review the AWMSG guidance.

#### **ACTION**

**AWPAG to review when legislative changes are published**

Mr Andrew Evans – left the meeting

### **15.0 AWMSG Medicines Strategy for Wales**

The Chairman presented the updated AWMSG Medicines Strategy for Wales and invited the group to comment prior to it being circulated for consultation. Jamie Hayes explained the background to the new format of the document. Mr Stefan Fec suggested a review of the wording of Page 3, Section 5: Aiming at Excellence. Members were invited to email comments to AWTTTC.

#### **ACTION**

**Comments to be directed to AWTTTC**

### **16.0 Supply and administration of intranasal fentanyl spray in non-specialist palliative inpatient settings**

The Chairman welcomed Dr Debbie Jenkins, Consultant in Palliative Medicine, co-author of the proposal for AWPAG to endorse the Anuerin Bevan Health Board protocol for the supply and administration of intranasal fentanyl spray as a template for good practice for use within NHS Wales. Dr Jenkins presented her proposal to the group. Clarification was sought that morphine remains the first treatment of choice for the management of chronic and breakthrough pain in palliative care and this should be made clearer in the document. With this proviso AWPAG endorsed the paper.

#### **ACTION**

**Dr Jenkins to present the amended paper to AWMSG in October**

### **17.0 AWPAG Project Update**

The Chairman provided feedback from the AWPAG Project meeting held on Tuesday 10<sup>th</sup> September 2013. The following projects were noted:

Update to the All Wales contraceptive guidance

Update to the All Wales anticoagulant guidance

Oral bisphosphonates

Update to the anticoagulant audit

Provision of polypharmacy workshops (training the trainer style)

Asthma step up / step down guidance

Update to the guidelines for administration of medicines to patients with swallowing difficulties

### **18.0 Implementation**

Mr Jamie Hayes provided the group with verbal update regarding ongoing work around an implementation framework by AWTTTC.

### **19.0 Patient and Public Involvement**

Mr Jamie Hayes presented the draft patient and public engagement strategy, produced by AWTTTC. Members were informed an external consultation process would soon be underway; comments from members, particularly the patient representative, were invited.

#### **ACTION**

**Members asked to comment directly to AWTTTC outside of the meeting**

### **20.0 AOB – Shingles Vaccination Programme**

Mrs Jane Barnard highlighted an issue relating to a recently introduced campaign of immunisation for shingles for over 70s. She expressed concern that as it was a live vaccine patients who were immunosuppressed were at significant risk of contracting shingles and that this information was not made clear in the Patient group directions (PGDs). The Chairman stated that this was an issue for the Chief Pharmacists primary care group to check individual PGDs and would be raised at their next meeting due to take place on 17<sup>th</sup> September 2013.

#### **ACTION**

**AWPAG Chair to approach the Chair of the Chief Pharmacists primary care group**

**The date of next meeting was confirmed - Thursday 5<sup>th</sup> December 2013.**

**There being no further business, the Chair closed the meeting.**